Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial

Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial

PURPOSE: This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR). MATERIALS AND METHODS: Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All p...

Full description

Bibliographic Details
Main Authors: Karen R Armbrust, Austin R Fox, Brett G Jeffrey, Patti Sherry, H Nida Sen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Taiwan Journal of Ophthalmology
Subjects:
autoimmunity
electroretinography
retinal degeneration
rituximab
visual fields
Online Access:http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=1;spage=64;epage=70;aulast=Armbrust

Internet

http://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=1;spage=64;epage=70;aulast=Armbrust

Similar Items